Latest news with #Lantern
Business Wire
7 hours ago
- Business
- Business Wire
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed with LP-284 and displays profound clinical activity in one of the most therapeutically challenging hematologic cancers. This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm Share The RADR®-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting. The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab). Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This remarkable clinical outcome supports LP-284's synthetic lethal mechanism and is an initial step towards a potential new paradigm for treating refractory aggressive lymphomas and B-cell malignancies. Paradigm-Shifting Observation of Complete Response in Therapeutically Exhausted Patient 'This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,' said Panna Sharma, President and CEO of Lantern Pharma. 'Our RADR® platform's systematic analysis of molecular vulnerabilities enabled us to rapidly advance LP-284 from computational concept to a clinical milestone in a patient in under three years at approximately $3 million — demonstrating how AI-driven precision has the promise to fundamentally reshape pharmaceutical innovation. This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.' LP-284, a computationally optimized next-generation acylfulvene, was systematically developed with guidance from Lantern's RADR® platform to exploit synthetic lethal interactions in cancer cells harboring specific DNA damage repair deficiencies. The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function — a precision approach aimed at delivering transformative clinical benefit for patients who have failed multiple prior treatment modalities. Potential to Address a Critical Therapeutic Void in Refractory DLBCL This patient's clinical journey exemplifies the devastating trajectory of aggressive DLBCL in the refractory setting. Despite achieving an initial complete metabolic response with CAR-T therapy (liso-cel) at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips — representing an extremely challenging clinical scenario. The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future paradigm-shifting alternative for treating therapeutically exhausted DLBCL patients. This encouraging outcome underscores LP-284's potential to address critical gaps in the therapeutic armamentarium for patients who have failed both conventional and cutting-edge immunotherapeutic approaches. Advancing Strategic Clinical Development and Global Expansion The complete metabolic response achievement positions LP-284 for accelerated development pathways and strengthens Lantern's strategic position in the competitive hematologic oncology landscape. This clinical milestone provides important confirmation of the company's systematic approach to therapeutic development and creates additional opportunities for international partnership expansion and collaborative research initiatives. Lantern's ongoing Phase 1 dose-escalation study (NCT06132503) is designed to evaluate LP-284's safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes. The trial's systematic design enables precise evaluation of LP-284's therapeutic potential across genetically defined patient populations, with a current focus on aggressive NHL subtypes including mantle cell lymphoma and high-grade B-cell lymphomas. LP-284's multiple FDA Orphan Drug Designations position the compound for potential expedited regulatory pathways and enhanced market exclusivity frameworks. Transforming Global Oncology Through Computational Precision This clinical development provides important confirmation of the transformative potential of Lantern's RADR® platform, which leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to assist in systematically identifying and optimizing therapeutic opportunities. The platform's computational efficiency enabled Lantern to rapidly advance the LP-284's program into the clinic in under three years at a cost of approximately $3 million — representing striking development efficiency compared to traditional pharmaceutical paradigms. The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations. Next Steps and Future Development Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials. About LP-284 LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed with guidance from Lantern's AI platform RADR®, LP-284 represents a novel therapeutic approach with potential to address critical gaps in the treatment of relapsed or refractory non-Hodgkin's lymphoma and other hematologic malignancies. The compound is currently being evaluated in a Phase 1 clinical trial (NCT06132503) to determine its safety profile, optimal dosing, and potential activity in patients with aggressive NHL subtypes who have failed standard therapies. LP-284 has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas, recognizing its potential to address significant unmet medical needs in rare cancer populations. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning with the aim of uncovering novel therapeutic opportunities, accelerating drug development timelines, and improving patient outcomes. The company's approach combines advanced computational biology with traditional pharmaceutical development to transform how cancer drugs are discovered and developed. For more information, visit: - Website: ( - LinkedIn: - X: @lanternpharma ( Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( or on the SEC's website at ( Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
The Hindu
09-07-2025
- The Hindu
This fine dine Chinese restaurant in Bengaluru brings dishes from four regions of China
For a long time in Bengaluru, pan Asian cuisine was ruling the restaurant circuit. It seems that is now passe, as we get more region-focussed menus. Case in point, Yan Yan, the new restaurant at The Ritz-Carlton, Bangalore. A fine dine restaurant that brings together dishes from Canton, Hakka, Sichuan and Hunan regions of China. Even though it launched last week, the restaurant is packed, a good sign. Yan Yan is in the same spot where Lantern, their previous Asian restaurant was. Shades of red, in typical oriental style dominate the decor. Blue vases, Chinese hand fans and lush silk fabric complete the look. It is spread over two levels, the lower floor overlooking a flowing water body. Yan Yan means a feast for the eyes. And in that vein, we are handed a menu on an iPad that is complete with pictures of each dish, so you can see what your dish will look like before you order it. The menu has sections such as cold plates, dim sum, hot plates, mains and desserts. The beautiful plating makes it hard to decide what to order. Hidden gems Each cocktail at Yan Yan is named after a jewel or a gem. The highlight for me is the Moonstone Elixir cocktail. A concoction of vodka, sparkling wine and bitter melon (yes that is a karela). It takes us by surprise, as it is fresh and light, with a hint of the bitter. Even the non-bitter gourd lovers on the table gave it their approval. Serpentine dew is made of Sichuan peppercorn infused tequila, tomato water and celery soda, and Jasper Ember has whiskey, homemade goji berry syrup and aromatic bitters. All the cocktails are Asian inspired, balanced and innovative. An array of small plates are brought to the table. The tofu skin and baby spinach salad is made of delicate bean curd skin, that is chewy and savoury. Served a stop crunchy wanton skin and greens, we really enjoy this. The petit greens and colossal crab with quail eggs is decent; the flavours are not much to write home about. Shaolin asparagus and water chestnut is crunchy with an umami-heavy dressing. We try a platter of dim sums too; the thin casing impresses us. Classic Chinese numbers We want to see what elevated Chinese is when it comes to the classics. So, for mains, we opt for Sichuan chicken, stir fried greens, noodles and crispy prawn. The chicken is the clear winner. A mildly spicy sauce, that is nutty and aromatic with juicy pieces of meat. The dried red chilies and cashew nuts add another dimension. The wok fried prosperity noodles are the perfect combo for this. We pick a delicate soy garlic sauce for the noodles. The truffle and tenderloin fried rice also comes highly recommended. Vegetarians should try the 12 Mile Farmed Mushrooms. The dish is made of five types of mushrooms — pioppino, shiitake, wood ear, eryngii and oyster— in a light gravy. Dessert too is a mix of classics and modern. The sesame mochi is warm and chewy and stuffed with a rich black sesame paste. The darsaan has tender coconut ice cream, atop a bed of fried noodles. Crunchy, sweet, cold and fruity, all in one. Warm service, comfort classics but elevated and creative cocktails won me over. I will be returning to try more. Cost for two ₹4,000. At Residency Road. For more details or reservations, call 9035416155
Yahoo
26-06-2025
- Health
- Yahoo
The best wrist braces for carpal tunnel syndrome of 2025, according to hand specialists and health experts
Pain, discomfort and numbness in your fingers can make everyday tasks like pushing a shopping cart or pulling the garbage can to the curb incredibly painful. And while hand and wrist pain can arise from any number of causes, a common culprit is carpal tunnel syndrome. CTS is a neurological condition that occurs when there's compression of the median nerve — one of the three major nerves of the forearm and hand. Pressure on that nerve often results in a tingling sensation, pain and numbness that can make living everyday life more challenging. While it's important to see a health care provider for wrist pain or numbness, one of the most common treatments for mild-to-moderate CTS is bracing. Dr. Raymond Hwang, vice president and medical director at Lantern, says, "Braces help keep the wrist in a neutral, slightly extended position, which relieves pressure on the median nerve as it travels through the carpal tunnel in the wrist. This can reduce numbness, tingling and pain."Certified hand therapist Brenda Cummings says, "Wrist braces for carpal tunnel work by keeping your wrist in a neutral position to alleviate pressure from the median nerve." To be effective, Cummings says, a brace should prevent you from being able to bend your wrist more than 15 degrees in any help find the best wrist braces for CTS, we spoke with orthopedic experts to learn what to look for in carpal tunnel-specific braces, and what to avoid. We learned that a rigid insert or stay (typically made of metal) is key to stabilizing the wrist. These stays may be found on the back of the wrist, the palm of the hand or on both sides. A dorsal support brace (those with stays on the back of the wrist) is often best for CTS since it prevents flexion, but depending on your level of pain or discomfort, a simple wrist brace or wrist wrap worn while sleeping may be the better our experts' feedback, we evaluated more than 20 wrist braces for CTS, rating each based on construction, materials used, breathability, brand reputation, user and in-house tester reviews, cost, comfort and efficacy. These are the eight wrist braces for carpal tunnel that made our cut. Update, June 25, 2025: We checked all product prices and availability. Our No. 1 pick for the best wrist brace for carpal tunnel remains unchanged. Three stages categorize the symptoms and level of severity of carpal tunnel syndrome. Stage 1: Frequently waking in the night with a sensation of a swollen, numb hand or severe pain that radiates from the wrist to the shoulder. There is also tingling in the hand and fingers. After waking, hand stiffness usually persists. Stage 2: The symptoms are present during the day, especially if you stay in the same position for prolonged periods or perform repeated movements or tasks with the hand and wrist. This is the stage where you may have lost so much feeling in your hands and fingers that you frequently drop things. Stage 3: This is the final stage where atrophy can set in and the median nerve may respond poorly even to more advanced treatments like surgical decompression. In this phase, sensory symptoms decline. Comfortable fit: Carpal tunnel braces keep your wrist in a neutral position. Immobilization is important because wrist flexion puts pressure on the median nerve; bracing prevents this pressure. However, in order for the brace to work, it needs to fit correctly. It should be snug enough to provide adequate support, but not so tight that it restricts circulation or causes skin irritation. Material: A big part of comfort has to do with quality materials. Neoprene is one of the best material choices since it offers compression, warmth, elasticity and breathability. Mesh fabric can also add to a brace's overall breathability. Softer materials, like memory foam, can provide padding for additional comfort. Some braces use copper-infused fabrics, which can help deodorize the brace. Most of these wrist braces are not machine-washable, but you can hand-wash some of them. Structure and design: Most braces have a rigid insert on either the dorsal side (i.e., the back of the wrist), the palmar side, or both. Small studies indicate a dorsal support brace may be best for carpal tunnel since it prevents flexion without adding more pressure to the median nerve. Palmar support can be beneficial, too; just make sure that the rigid stays don't press in on the median nerve or that they're removable. Length is also important. "A wrist brace that is too short may apply more pressure to the median nerve," says Cummings. Look for a wrist brace that doesn't stop directly at the wrist and instead extends about halfway up the forearm. Cost: Finally, cost is something to consider. The best wrist brace for you is one that is comfortable and effective, but more expensive doesn't necessarily mean better. To determine the best carpal tunnel braces, our team looked at over 20 different wrist braces and evaluated each based on their efficacy. The truth is, there are many wrist braces on the market, but not all of them work well to alleviate the specific symptoms of carpal tunnel syndrome. We considered factors like the overall structure and design of the brace, the amount of stability it provides and how comfortable it is to wear. Finally, we consulted two orthopedic experts, including a hand pain specialist and an orthopedic surgeon to get their input on which braces are the best options for CTS. Dr. John Thomas, a board-certified hand surgeon, says that wrist braces can be extremely beneficial for mild to moderate carpal tunnel, especially when used overnight. "Most people like to curl up and fully flex their wrists at night," he says. "This places pressure upon the median nerve in the carpal tunnel and increases symptoms." In addition to bracing, treatments for CTS include oral anti-inflammatory medication, steroid injections and, in severe cases, surgery to decompress the carpal tunnel and increase space for the median nerve. You shouldn't consider wrist braces as a permanent fixture in your life. Instead, Thomas says, they're best worn for a few weeks. If symptoms don't improve, it's a sign you might need to try a more intensive form of treatment. Dr. Melissa Boyette, an orthopedic surgeon, says, "I would caution against wearing a brace longer than a few weeks if a physician has not evaluated you." She warns that prolonged bracing can lead to stiffness and weakness in the forearms and wrists. Hwang recommends taking frequent hand/wrist stretching breaks, especially for those with repetitive hand motions at work. He also says, "Prevention through ergonomic workstations, exercises, and avoiding excessive wrist bending is important for those at risk." You can also try oral anti-inflammatory medication or a pain-relieving cream for immediate relief. Dr. Melissa Boyette, orthopedic surgeon; hand and wrist specialist, Bradenton, Fla. Brenda Cummings, OTD, OTR, CHT, certified hand therapist, Fort Collins, Colo. Dr. Raymond Hwang, orthopedic surgeon and medical director at Hinge Health Dr. John Thomas, orthopedic hand surgeon, New York City Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
Scottish Sun
22-06-2025
- Scottish Sun
One of the world's most beautiful train stations that looks like ‘Gotham City' is home to weirdly-beautiful Burger King
And we round up the UK's most beautiful train stations ON TRACK One of the world's most beautiful train stations that looks like 'Gotham City' is home to weirdly-beautiful Burger King Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) ONE of the world's most beautiful stations has been described as looking like something from a comic book. Helsinki Central Train Station in Finland has been named one of the most stunning train stations by both Lonely Planet and BBC. Sign up for Scottish Sun newsletter Sign up 5 Helsinki Central Train Station has been named one of the world's most beautiful Credit: Alamy 5 Some have said it looks like Batman's Gotham City Credit: Alamy It dates back as far as the 1860s which is when the railway tracks were first laid, although the main building opened in 1919. The Art Nouveau station also has a huge glass roof inside that was added in 2001. The main features outside are the two statues, called the Lyhdynkantajat (Lantern Bearers) on either side of the entrance, as well as the huge clock tower. One tourist wrote online: "The central station wouldn't look out of place in Gotham City with the characters built into either side of the main entrance." Another agreed: "One of the most Impressive buildings in Helsinki. To me looks Like from Gotham city in the Batman movies." Around 240,000 people use the station per day, as it is used as a transport hub for both commuters and long-haul travellers. Yet only half of those people are actually using the station for transport purposes, with the other half visiting it as a tourist attraction. It is so popular, it is is actually the most visited building in all of Finland. Along with 19 platforms, there are 15 cafes and restaurants including everything from juice bars and sandwich delis to fancier wine bars and beer stops. And the station is currently undergoing a huge renovation with improvements to the platform waiting area. Huge new train station to open in world's most popular city 5 The two statues outside are a famous feature Credit: Alamy As well as the addition of more seating, digital displays and automatic doors, a new brewery, restaurant and food court are also being added. Passengers are warned of temporary restrictions because of this until spring 2026. The Burger King in Helsinki's Central Station is even praised for being on of the most beautiful in the world. Tourists enter through a glass archway and are met by a huge chandelier hanging outside. 5 Inside are more than 15cafes, bars and restaurants Credit: Alamy One Youtuber said: "Absolutely the fanciest Burger King in the world, it's got to be." Visit in the winter months as you will also post a huge outdoor ice skating rink outside the station as well. Here's what it is like to go on a European train holiday, including a stop at the train station. For other beautiful train stations, Schafbergbahn Station in St. Wolfgang, Austria was named the most beautiful by architecture and design award Prix Versailles. Milan's main train station as well as Liege-Guillemins railway station in Belgium have also been praised. And we've rounded up the prettiest ones in the UK. 5 The train station renovations are set to be complete by 2026 Credit: Alamy
The Irish Sun
22-06-2025
- The Irish Sun
One of the world's most beautiful train stations that looks like ‘Gotham City' is home to weirdly-beautiful Burger King
ONE of the world's most beautiful stations has been described as looking like something from a comic book. Helsinki Central Train Station in Finland has been named one of the most stunning train stations by both Lonely Planet and BBC. Advertisement 5 Helsinki Central Train Station has been named one of the world's most beautiful Credit: Alamy 5 Some have said it looks like Batman's Gotham City Credit: Alamy It dates back as far as the 1860s which is when the railway tracks were first laid, although the main building opened in 1919. The Art Nouveau station also has a huge glass roof inside that was added in 2001. The main features outside are the two statues, called the Lyhdynkantajat (Lantern Bearers) on either side of the entrance, as well as the huge clock tower. One tourist wrote online: "The central station wouldn't look out of place in Gotham City with the characters built into either side of the main entrance." Advertisement Read more on train stations Another agreed: "One of the most Impressive buildings in Helsinki. To me looks Like from Gotham city in the Batman movies." Around 240,000 people use the station per day, as it is used as a transport hub for both commuters and long-haul travellers . Yet only half of those people are actually using the station for transport purposes, with the other half visiting it as a tourist attraction. It is so popular, it is is actually the most visited building in all of Finland. Advertisement Most read in News Travel Along with 19 platforms, there are 15 cafes and restaurants including everything from juice bars and sandwich delis to fancier wine bars and beer stops. And the station is currently undergoing a huge renovation with improvements to the platform waiting area. Huge new train station to open in world's most popular city 5 The two statues outside are a famous feature Credit: Alamy As well as the addition of more seating, digital displays and automatic doors, a new brewery, restaurant and food court are also being added. Advertisement Passengers are warned of temporary restrictions because of this until spring 2026. The Burger King in Helsinki's Central Station is even praised for being on of the most beautiful in the world. Tourists enter through a glass archway and are met by a huge chandelier hanging outside. 5 Inside are more than 15cafes, bars and restaurants Credit: Alamy Advertisement One Youtuber said: "Absolutely the fanciest Burger King in the world, it's got to be." Visit in the winter months as you will also post a huge outdoor ice skating rink outside the station as well. Here's what it is like to go on a For other beautiful train stations architecture and design award Prix Versailles. Advertisement Belgium have also been praised. And we've rounded up the prettiest ones in the UK. 5 The train station renovations are set to be complete by 2026 Credit: Alamy Advertisement
